SELLAS Life Sciences (SLS) Profit After Tax (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Profit After Tax for 17 consecutive years, with -$8.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 44.5% year-over-year to -$8.4 million; the TTM figure through Mar 2026 stood at -$29.5 million (down 8.7% YoY), while the FY2025 annual figure was -$26.9 million, up 12.89% from the prior year.
• Profit After Tax slipped to -$8.4 million in Q1 2026 per SLS's latest filing, from -$7.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$5.8 million in Q1 2025 and bottomed at -$16.7 million in Q1 2022.
• Historically, Profit After Tax has averaged -$8.5 million across 5 years, with a median of -$8.1 million in 2023.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 596.8% — and 2025, when it surged 39.23%.
• SELLAS Life Sciences' Profit After Tax stood at -$9.1 million in 2022, then increased by 10.8% to -$8.1 million in 2023, then increased by 17.2% to -$6.7 million in 2024, then fell by 14.22% to -$7.7 million in 2025, then declined by 9.16% to -$8.4 million in 2026.
• Business Quant data shows SLS's Profit After Tax at -$8.4 million in Q1 2026, -$7.7 million in Q4 2025, and -$6.8 million in Q3 2025.